GPR43 AND OBESITY

Short chain fatty acids and GPR43 in human health and disease

Coordinatore	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE    more  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Tatjana Cognome: Palalic Email: send email Telefono: 442076000000 Fax: 442076000000
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	75˙000 €
EC contributo	75˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-RG
Funding Scheme	MC-IRG
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-04-01   -   2013-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Tatjana Cognome: Palalic Email: send email Telefono: 442076000000 Fax: 442076000000	UK (LONDON)	coordinator	75˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'These studies will determine the physiological impact of short chain fatty acids (SCFA) which activate the G-coupled protein receptor 43 (GPR43) as dietary supplementation in treating obesity and type 2 diabetes. Non-digestible carbohydrates (NDC) are carbohydrates which are indigestible in the small intestine, but are broken down in the colon by the fermentation process of bacteria. SCFA are the major products of carbohydrate fermentation and bind to a receptor called GPR43 which is expressed on adipocytes, immune cells, pancreatic beta-cells and enteroendocrine cells that release appetite-suppressing hormones glucagon like peptide-1 (GLP-1) and peptide YY (PYY). Therefore, it is suggestive that this receptor provides a cross-talk between different organs and tissues, linking metabolism with the innate immune system. These studies aim to test the hypothesis that administration of the SCFA propionate reduces appetite by inducing anorectic gut hormone release, improves glucose stimulated insulin secretion, reduces body weight, induces adipocyte proliferation and differentiation, and regulates activation of the immune system and systemic inflammation. Should these studies prove positive then this work will propose a novel treatment option for obesity and type 2 diabetes.'